Acquired TTP: ADAMTS13 meets the immune system

Blood Reviews

Volumn 28, Issue 6, 2014, Pages 227-234

  Verbij, Fabian C ^a   Fijnheer, Rob ^b   Voorberg, Jan ^a   Sorvillo, Nicoletta ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

ADAMTS13; Antibodies; Glycosylation; Molecular mimicry; Review; Thrombotic thrombocytopenic purpura; TTP

Indexed keywords

CORTICOSTEROID; CYCLOSPORIN; HLA DRB1 ANTIGEN; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN A1 ANTIBODY; IMMUNOGLOBULIN A2 ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G2 ANTIBODY; IMMUNOGLOBULIN G3 ANTIBODY; IMMUNOGLOBULIN G4 ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; RECOMBINANT VON WILLEBRAND FACTOR; RITUXIMAB; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR CLEAVING PROTEINASE; ADAM PROTEIN; ADAMTS13 PROTEIN, HUMAN; AUTOANTIBODY;

ANTIGEN ANTIBODY COMPLEX; ANTIGEN PRESENTING CELL; ANTIGEN RECOGNITION; AUTOIMMUNITY; B LYMPHOCYTE; BACTERIAL INFECTION; CD4+ T LYMPHOCYTE; DENDRITIC CELL; GLYCOSYLATION; HUMAN; IMMUNE SYSTEM; IMMUNOREACTIVITY; IMMUNOSUPPRESSIVE TREATMENT; INNATE IMMUNITY; MOLECULAR MIMICRY; NONHUMAN; PLASMAPHERESIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; REVIEW; RISK FACTOR; T LYMPHOCYTE ACTIVATION; THROMBOTIC THROMBOCYTOPENIC PURPURA; VIRUS INFECTION; BLOOD; IMMUNOLOGY;

ADAM PROTEINS; ANTIGEN-PRESENTING CELLS; AUTOANTIBODIES; HUMANS; PURPURA, THROMBOTIC THROMBOCYTOPENIC;

EID: 84923840023     PISSN: 0268960X     EISSN: 15321681     Source Type: Journal    
DOI: 10.1016/j.blre.2014.07.004     Document Type: Article

References (100)

1. Zheng X.L., Kaufman R.M., Goodnough L.T., Sadler J.E. Effect of plasma exchange on plasma ADAMTS13 metalloprotease activity, inhibitor level, and clinical outcome in patients with idiopathic and nonidiopathic thrombotic thrombocytopenic purpura. Blood 2004, 103(11):4043-4049.
2. Shenkman B., Einav Y. Thrombotic thrombocytopenic purpura and other thrombotic microangiopathic hemolytic anemias: diagnosis and classification. Autoimmun Rev 2014, 13:584-586.
3. Bapani S., Epperla N., Kasirye Y., Mercier R., Garcia-Montilla R. ADAMTS13 deficiency and thrombotic thrombocytopenic purpura associated with trimethoprim-sulfamethoxazole. Clin Med Res Jun 1 2013, 11(2):86-90.
4. Zhou W., Inada M., Lee T.-P., Benten D., Lyubsky S., Bouhassira E.E., et al. ADAMTS13 is expressed in hepatic stellate cells. Lab Invest J Tech Methods Pathol Jun 2005, 85(6):780-788.
5. Uemura M., Tatsumi K., Matsumoto M., Fujimoto M., Matsuyama T., Ishikawa M., et al. Localization of ADAMTS13 to the stellate cells of human liver. Blood Aug 1 2005, 106(3):922-924.
6. Turner N., Nolasco L., Tao Z., Dong J.-F., Moake J. Human endothelial cells synthesize and release ADAMTS-13. J Thromb Haemost Jun 1 2006, 4(6):1396-1404.
7. Shang D., Zheng X.W., Niiya M., Zheng X.L. Apical sorting of ADAMTS13 in vascular endothelial cells and Madin-Darby canine kidney cells depends on the CUB domains and their association with lipid rafts. Blood Oct 1 2006, 108(7):2207-2215.
8. Soejima K., Nakamura H., Hirashima M., Morikawa W., Nozaki C., Nakagaki T. Analysis on the molecular species and concentration of circulating ADAMTS13 in Blood. J Biochem (Tokyo) Jan 2006, 139(1):147-154.
9. Feys H.B., Anderson P.J., Vanhoorelbeke K., Majerus E.M., Sadler J.E. Multi-step binding of ADAMTS-13 to von Willebrand factor. J Thromb Haemost Dec 1 2009, 7(12):2088-2095.
10. Siediecki C.A., Lestini B.J., Kottke-Marchant K.K., Eppell S.J., Wilson D.L., Marchant R.E. Shear-dependent changes in the three-dimensional structure of human von Willebrand factor. Blood Oct 15 1996, 88(8):2939-2950.
11. Dong J., Moake J.L., Nolasco L., Bernardo A., Arceneaux W., Shrimpton C.N., et al. ADAMTS-13 rapidly cleaves newly secreted ultralarge von Willebrand factor multimers on the endothelial surface under flowing conditions. Blood Dec 1 2002, 100(12):4033-4039.
12. Xiang Y., de Groot R., Crawley J.T.B., Lane D.A. Mechanism of von Willebrand factor scissile bond cleavage by a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13 (ADAMTS13). Proc Natl Acad Sci Jun 24 2011, 108(28):11602-11607.
13. Dong J.-F. Cleavage of ultra-large von Willebrand factor by ADAMTS-13 under flow conditions. J Thromb Haemost Aug 2005, 3(8):1710-1716.
14. Motto D.G. Shigatoxin triggers thrombotic thrombocytopenic purpura in genetically susceptible ADAMTS13-deficient mice. J Clin Invest Oct 1 2005, 115(10):2752-2761.
15. Scheiflinger F. Nonneutralizing IgM and IgG antibodies to von Willebrand factor-cleaving protease (ADAMTS-13) in a patient with thrombotic thrombocytopenic purpura. Blood Nov 1 2003, 102(9):3241-3243.
16. Hovinga J.A.K., Lämmle B. Role of ADAMTS13 in the pathogenesis, diagnosis, and treatment of thrombotic thrombocytopenic purpura. ASH Educ Program Book 2012, 2012(1):610-616.
17. Bentley M.J., Lehman C.M., Blaylock R.C., Wilson A.R., Rodgers G.M. The utility of patient characteristics in predicting severe ADAMTS13 deficiency and response to plasma exchange: ADAMTS13 DEFICIENCY AND PLASMA EXCHANGE. Transfusion (Paris) Feb 11 2010, 50(8):1654-1664.
18. Clark W.F., Forzley B.R., Sontrop J.M., Kadri A., Moist L.M., Suri R.S., et al. TTP/HUS: observational studies generate hypotheses that lead to randomized controlled trials. Kidney Int Feb 2009, 75:S50-S51.
19. Rock G.A., Shumak K.H., Buskard N.A., Blanchette V.S., Kelton J.G., Nair R.C., et al. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group. N Engl J Med Aug 8 1991, 325(6):393-397.
20. Belondee F., Buffer M., Coindre J.P., Munoz-Bongrand N., Malot S., Pène F., et al. Splenectomy and/or cyclophosphamide as salvage therapies in thrombotic thrombocytopenic purpura: The French TMA Reference Centre experience. Transfusion 2012, 52(11):2436-2444.
21. Yilmaz M., Eskazan A.E., Unsal A., Taninmis H., Kara E., Cetiner M., et al. Cyclosporin A therapy on idiopathic thrombotic thrombocytopenic purpura in the relapse setting: two case reports and a review of the literature: CSA Therapy in Relapsed Idiopathic TTP. Transfusion (Paris) Jul 2013, 53(7):1586-1593.
22. Westwood J.-P., Webster H., McGuckin S., McDonald V., Machin S.J., Scully M. Rituximab for thrombotic thrombocytopenic purpura: benefit of early administration during acute episodes and use of prophylaxis to prevent relapse. J Thromb Haemost Mar 2013, 11(3):481-490.
23. Shortt J., Oh D.H., Opat S.S. ADAMTS13 antibody depletion by bortezomib in thrombotic thrombocytopenic purpura. N Engl J Med Jan 3 2013, 368(1):90-92.
24. Mazepa M.A., Raval J.S., Moll S., Ma A., Park Y.A. Bortezomib induces clinical remission and reduction of ADAMTS13 inhibitory antibodies in relapsed refractory idiopathic thrombotic thrombocytopenic purpura. Br J Haematol 2014, 164:888-902.
25. Van Balen T., Schreuder M.F., de Jong H., van de Kar N.C.A.J. Refractory thrombotic thrombocytopenic purpura in a 16-year-old girl: successful treatment with bortezomib. Eur J Haematol Jan 1 2014, 92(1):80-82.
26. Pos W., Luken B.M., Sorvillo N., Hovinga J.A.K., Voorberg J. Humoral immune response to ADAMTS13 in acquired thrombotic thrombocytopenic purpura: auto-antibodies to ADAMTS13. J Thromb Haemost Jul 2011, 9(7):1285-1291.
27. Ferrari S., Scheiflinger F., Rieger M., Mudde G., Wolf M., Coppo P., et al. Prognostic value of anti-ADAMTS13 antibody features (Ig isotype, titer, and inhibitory effect) in a cohort of 35 adult French patients undergoing a first episode of thrombotic microangiopathy with undetectable ADAMTS13 activity. Blood Apr 1 2007, 109(7):2815-2822.
28. Ferrari S., Mudde G.C., Rieger M., Veyradier A., Kremer Hovinga J.A., Scheiflinger F. IgG subclass distribution of anti-ADAMTS13 antibodies in patients with acquired thrombotic thrombocytopenic purpura. J Thromb Haemost Oct 2009, 7(10):1703-1710.
29. Merrett J., Barnetson R.S., Burr M.L., Merrett T.G. Total and specific IgG4 antibody levels in atopic eczema. Clin Exp Immunol Jun 1984, 56(3):645.
30. Rieger M., Mannucci P.M., Hovinga J.A.K., Herzog A., Gerstenbauer G., Konetschny C., et al. ADAMTS13 autoantibodies in patients with thrombotic microangiopathies and other immunomediated diseases. Blood Aug 15 2005, 106(4):1262-1267.
31. Ferrari S., Knöbl P., Kolovratova V., Plaimauer B., Turecek P.L., Varadi K., et al. Inverse correlation of free and immune complex-sequestered anti-ADAMTS13 antibodies in a patient with acquired thrombotic thrombocytopenic purpura. J Thromb Haemost 2012, 10(1):156-158.
32. RéTi M., Farkas P., Csuka D., RáZsó K., Schlammadinger Á., Udvardy M.L., et al. Complement activation in thrombotic thrombocytopenic purpura: Complement activation in TTP. J Thromb Haemost May 2012, 10(5):791-798.
33. Ferrari S., Palavra K., Gruber B., Hovinga J.A.K., Knöbl P., Caron C., et al. Persistence of circulating ADAMTS13-specific immune complexes in patients with acquired thrombotic thrombocytopenic purpura. Haematologica Apr 2014, 99(4):779-787.
34. Lotta L.A., Valsecchi C., Pontiggia S., Mancini I., Cannavò A., Artoni A., et al. Measurement and prevalence of circulating ADAMTS13-specific immune complexes in autoimmune thrombotic thrombocytopenic purpura. J Thromb Haemost Mar 2014, 12(3):329-336.
35. Westwood J.-P., Langley K., Heelas E., Machin S.J., Scully M. Complement and cytokine response in acute Thrombotic Thrombocytopenic Purpura. Br J Haematol Mar 2014, 164(6):858-866.
36. Chapin J., Weksler B., Magro C., Laurence J. Eculizumab in the treatment of refractory idiopathic thrombotic thrombocytopenic purpura. Br J Haematol Jun 2012, 157(6):772-774.
37. Luken B.M., Turenhout E.A.M., Hulstein J.J.J., Van Mourik J.A., Fijnheer R., Voorberg J. The spacer domain of ADAMTS13 contains a major binding site for antibodies in patients with thrombotic thrombocytopenic purpura. Thromb Haemost Feb 2005, 93(2):267-274.
38. Luken B.M., Turenhout E.A.M., Kaijen P.H.P., Greuter M.J., Pos W., van Mourik J.A., et al. Amino acid regions 572-579 and 657-666 of the spacer domain of ADAMTS13 provide a common antigenic core required for binding of antibodies in patients with acquired TTP. Thromb Haemost Sep 2006, 96(3):295-301.
39. Pos W., Crawley J.T.B., Fijnheer R., Voorberg J., Lane D.A., Luken B.M. An autoantibody epitope comprising residues R660, Y661, and Y665 in the ADAMTS13 spacer domain identifies a binding site for the A2 domain of VWF. Blood Dec 23 2009, 115(8):1640-1649.
40. Wang A., Liu F., Dong N., Ma Z., Zhang J., Su J., et al. Thrombospondin-1 and ADAMTS13 competitively bind to VWF A2 and A3 domains in vitro. Thromb Res Oct 2010, 126(4):e260-e265.
41. Pos W., Sorvillo N., Fijnheer R., Feys H.B., Kaijen P.H.P., Vidarsson G., et al. Residues Arg568 and Phe592 contribute to an antigenic surface for anti-ADAMTS13 antibodies in the spacer domain. Haematologica Jun 28 2011, 96(11):1670-1677.
42. Jian C., Xiao J., Gong L., Skipwith C.G., Jin S.-Y., Kwaan H.C., et al. Gain-of-function ADAMTS13 variants that are resistant to autoantibodies against ADAMTS13 in patients with acquired thrombotic thrombocytopenic purpura. Blood 2012, 119(16):3836-3843.
43. Zheng X.L., Wu H.M., Shang D., Falls E., Skipwith C.G., Cataland S.R., et al. Multiple domains of ADAMTS13 are targeted by autoantibodies against ADAMTS13 in patients with acquired idiopathic thrombotic thrombocytopenic purpura. Haematologica Apr 7 2010, 95(9):1555-1562.
44. Luken B.M., Kaijen P.H.P., Turenhout E.A.M., Kremer Hovinga J.A., Van Mourik J.A., Fijnheer R., et al. Multiple B-cell clones producing antibodies directed to the spacer and disintegrin/thrombospondin type-1 repeat 1 (TSP1) of ADAMTS13 in a patient with acquired thrombotic thrombocytopenic purpura. J Thromb Haemost 2006, 4(11):2355-2364.
45. Bao J., Xiao J., Mao Y., Zheng X.L. Carboxyl terminus of ADAMTS13 directly inhibits platelet aggregation and ultra large von Willebrand factor string formation under flow in a free-thiol-dependent manner. Arterioscler Thromb Vasc Biol Feb 2014, 34(2):397-407.
46. Pos W., Luken B.M., Hovinga J.A., Turenhout E.A., Scheiflinger F., Dong J.F., et al. VH1-69 germline encoded antibodies directed towards ADAMTS13 in patients with acquired thrombotic thrombocytopenic purpura. J Thromb Haemost Mar 2009, 7(3):421-428.
47. Siegel D., Ostertag E. Inhibitory monoclonal autoantibodies cloned from TTP patients show restricted gene usage, inhibit murine ADAMTS13, and are blocked by rabbit anti-idiotypic antibodies. Blood 2006, 108:31a.
48. Sui J., Hwang W.C., Perez S., Wei G., Aird D., Chen L.M., et al. Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses. Nat Struct Mol Biol Mar 2009, 16(3):265-273.
49. Carbonari M., Caprini E., Tedesco T., Mazzetta F., Tocco V., Casato M., et al. Hepatitis C virus drives the unconstrained monoclonal expansion of VH1-69-expressing memory B cells in type II cryoglobulinemia: a model of infection-driven lymphomagenesis. J Immunol May 15 2005, 174(10):6532-6539.
50. Marasca R., Vaccari P., Luppi M., Zucchini P., Castelli I., Barozzi P., et al. Immunoglobulin gene mutations and frequent use of VH1-69 and VH4-34 segments in hepatitis C virus-positive and hepatitis C virus-negative nodal marginal zone B-cell lymphoma. Am J Pathol Jul 2001, 159(1):253-261.
51. Studt J.-D., Hovinga J.A.K., Radonic R., Gasparovic V., Ivanovic D., Merkler M., et al. Familial acquired thrombotic thrombocytopenic purpura: ADAMTS13 inhibitory autoantibodies in identical twins. Blood Jun 1 2004, 103(11):4195-4197.
52. Coppo P., Busson M., Veyradier A., Wynckel A., Poullin P., Azoulay E., et al. HLA-DRB1*11: a strong risk factor for acquired severe ADAMTS13 deficiency-related idiopathic thrombotic thrombocytopenic purpura in Caucasians. J Thromb Haemost Apr 2010, 8(4):856-859.
53. Scully M., Brown J., Patel R., Mcdonald V., Brown C.J., Machin S. Human leukocyte antigen association in idiopathic thrombotic thrombocytopenic purpura: evidence for an immunogenetic link. J Thromb Haemost Feb 2010, 8(2):257-262.
54. John M.-L., Hitzler W., Scharrer I. The role of human leukocyte antigens as predisposing and/or protective factors in patients with idiopathic thrombotic thrombocytopenic purpura. Ann Hematol Dec 28 2011, 91(4):507-510.
55. Schaller M., Studt J.-D., Voorberg J., Kremer Hovinga J.A. Acquired thrombotic thrombocytopenic purpura: development of an autoimmune response. Hamostaseologie Feb 27 2013, 33(2):121-130.
56. Bettoni G., Palla R., Valsecchi C., Consonni D., Lotta L.A., Trisolini S.M., et al. ADAMTS-13 activity and autoantibodies classes and subclasses as prognostic predictors in acquired thrombotic thrombocytopenic purpura: Prognostic biomarkers in acquired TTP. J Thromb Haemost Aug 2012, 10(8):1556-1565.
57. Cataland S.R., Jin Ming, Ferketich A.K., Kennedy M.S., Kraut E.H., George J.N., et al. An evaluation of ciclosporin and corticosteroids individually as adjuncts to plasma exchange in the treatment of thrombotic thrombocytopenic purpura. Br J Haematol Jan 2007, 136(1):146-149.
58. Burgdorf S., Kautz A., Bohnert V., Knolle P.A., Kurts C. Distinct pathways of antigen uptake and intracellular routing in CD4 and CD8 T cell activation. Science Apr 27 2007, 316(5824):612-616.
59. Reinhardt R.L., Liang H.-E., Locksley R.M. Cytokine-secreting follicular T cells shape the antibody repertoire. Nat Immunol Mar 1 2009, 10(4):385-393.
60. Sorvillo N., Pos W., van den Berg L.M., Fijnheer R., Martinez-Pomares L., Geijtenbeek T.B., et al. The macrophage mannose receptor promotes uptake of ADAMTS13 by dendritic cells. Blood 2012, 119(16):3828-3835.
61. Sorvillo N., van Haren S.D., Kaijen P.H., ten Brinke A., Fijnheer R., Meijer A.B., et al. Preferential HLA-DRB1*11-dependent presentation of CUB2-derived peptides by ADAMTS13-pulsed dendritic cells. Blood Jan 31 2013, 121(17):3502-3510.
62. Verreck F.A.W., Poel A., Drijfhout J.W., Amons R., Coligan J.E., Koning F. Natural peptides isolated from Gly86/Val86-containing variants of HLA-DR1,-DR 11, -DR13, and -DR52. Immunogenetics Nov 1996, 43(6):392-397.
63. Wucherpfennig K.W., Call M.J., Deng L., Mariuzza R. Structural alterations in peptide-MHC recognition by self-reactive T cell receptors. Curr Opin Immunol 2009, 21(6):590-595.
64. Lee H.-M., Bautista J.L., Scott-Browne J., Mohan J.F., Hsieh C.-S. A broad range of self-reactivity drives thymic regulatory T cell selection to limit responses to self. Immunity Sep 21 2012, 37(3):475-486.
65. Bouneaud C., Kourilsky P., Bousso P. Impact of negative selection on the T cell repertoire reactive to a self-peptide: a large fraction of T cell clones escapes clonal deletion. Immunity Dec 2000, 13(6):829-840.
66. Zehn D., Bevan M.J. T cells with low avidity for a tissue-restricted antigen routinely evade central and peripheral tolerance and cause autoimmunity. Immunity Aug 2006, 25(2):261-270.
67. Kranzer K., Eckhardt A., Aigner M., Knoll G., Deml L., Speth C., et al. Induction of maturation and cytokine release of human dendritic cells by helicobacter pylori. Infect Immun Aug 2004, 72(8):4416-4423.
68. Hogquist K.A., Baldwin T.A., Jameson S.C. Central tolerance: learning self-control in the thymus. Nat Rev Immunol Oct 2005, 5(10):772-782.
69. Kosugi N., Tsurutani Y., Isonishi A., Hori Y., Matsumoto M., Fujimura Y. Influenza A infection triggers thrombotic thrombocytopenic purpura by producing the anti-ADAMTS13 IgG inhibitor. Intern Med 2010, 49(7):689-693.
70. Gunther K., Garizio D., Nesara P. ADAMTS13 activity and the presence of acquired inhibitors in human immunodeficiency virus-related thrombotic thrombocytopenic purpura. Transfusion (Paris) Sep 2007, 47(9):1710-1716.
71. Kok R.H., Wolfhagen M.J., Klosters G. A syndrome resembling thrombotic thrombocytopenic purpura associated with human parvovirus B19 infection. Clin Infect Dis Off Publ Infect Dis Soc Am Jan 15 2001, 32(2):311-312.
72. Franchini M. Thrombotic thrombocytopenic purpura: proposal of a new pathogenic mechanism involving Helicobacter pylori infection. Med Hypotheses 2005, 65(6):1128-1131.
73. Yagita M., Uemura M., Nakamura T., Kunitomi A., Matsumoto M., Fujimura Y. Development of ADAMTS13 inhibitor in a patient with hepatitis C virus-related liver cirrhosis causes thrombotic thrombocytopenic purpura. J Hepatol Mar 2005, 42(3):420-421.
74. Kiki I., Gundogdu M., Albayrak B., Bilgic Y. Thrombotic thrombocytopenic purpura associated with Brucella infection. Am J Med Sci Mar 2008, 335(3):230-232.
75. Talebi T., Fernandez-Castro G., Montero A.J., Stefanovic A., Lian E. A case of severe thrombotic thrombocytopenic purpura with concomitant Legionella pneumonia: review of pathogenesis and treatment. Am J Ther Sep 2011, 18(5):e180-e185.
76. Kojima Y., Ohashi H., Nakamura T., Nakamura H., Yamamoto H., Miyata Y., et al. Acute thrombotic thrombocytopenic purpura after pneumococcal vaccination. Blood Coagul Fibrinolysis Jan 2014, 25.
77. Sfriso P., Ghirardello A., Botsios C., Tonon M., Zen M., Bassi N., et al. Infections and autoimmunity: the multifaceted relationship. J Leukoc Biol Mar 2010, 87(3):385-395.
78. Szabó T.G., Palotai R., Antal P., Tokatly I., Tóthfalusi L., Lund O., et al. Critical role of glycosylation in determining the length and structure of T cell epitopes. Immunome Res Sep 24 2009, 5(1):4.
79. la Herrán-Arita AK De, Kornum B.R., Mahlios J., Jiang W., Lin L., Hou T., et al. CD4+ T cell autoimmunity to hypocretin/orexin and cross-reactivity to a 2009 H1N1 influenza A epitope in narcolepsy. Sci Transl Med Dec 18 2013, 5(216):216ra176.
80. Wang P., Sidney J., Dow C., Mothé B., Sette A., Peters B. A systematic assessment of MHC class II peptide binding predictions and evaluation of a consensus approach. PLoS Comput Biol Apr 2008, 4(4):e1000048.
81. Wang P., Sidney J., Kim Y., Sette A., Lund O., Nielsen M., et al. Peptide binding predictions for HLA DR, DP and DQ molecules. BMC Bioinforma 2010, 11:568.
82. Limmathurotsakul D., Dance D.A.B., Wuthiekanun V., Kaestli M., Mayo M., Warner J., et al. Systematic review and consensus guidelines for environmental sampling of Burkholderia pseudomallei. PLoS Negl Trop Dis Mar 21 2013, 7(3):e2015.
83. Herwaldt B.L. Leishmaniasis. Lancet Oct 2 1999, 354(9185):1191-1199.
84. Albrecht H., Sobottka I., Emminger C., Jablonowski H., Just G., Stoehr A., et al. Visceral leishmaniasis emerging as an important opportunistic infection in HIV-infected persons living in areas nonendemic for Leishmania donovani. Arch Pathol Lab Med Feb 1996, 120(2):189-198.
85. Yin Y., Li Y., Kerzic M.C., Martin R., Mariuzza R.A. Structure of a TCR with high affinity for self-antigen reveals basis for escape from negative selection. EMBO J 2011, 30(6):1137-1148.
86. Al-Ghouleh A., Johal R., Sharquie I.K., Emara M., Harrington H., Shakib F., et al. The glycosylation pattern of common allergens: the recognition and uptake of Der p 1 by epithelial and dendritic cells is carbohydrate dependent. PLoS ONE Mar 30 2012, 7(3):e33929.
87. Sorvillo N., Kaijen P.H., Matsumoto M., Fujimura Y., van der Zwaan C., Verbij F.C., et al. Identification of N-linked glycosylation and putative O-fucosylation, C-mannosylation sites in plasma derived ADAMTS13. J. Thrombosis and Haemostasis May 2014, 12(5):670-679.
88. Kreisman L.S., Cobb B.A. Infection, inflammation and host carbohydrates: a glyco-evasion hypothesis. Glycobiology Aug 1 2012, 22(8):1019-1030.
89. George J.N. How I treat patients with thrombotic thrombocytopenic purpura: 2010. Blood Nov 18 2010, 116(20):4060-4069.
90. Bhagirath V.C., Kelton J.G., Moore J., Arnold D.M. Rituximab maintenance for relapsed refractory thrombotic thrombocytopenic purpura. Transfusion (Paris) Dec 2012, 52(12):2517-2523.
91. Hershko K., Simhadri V.L., Blaisdell A., Hunt R.C., Newell J., Tseng S.C., et al. Cyclosporin A impairs the secretion and activity of ADAMTS13 (a disintegrin and metalloprotease with thrombospondin type 1 repeat). J Biol Chem Nov 9 2012, 287(53):44361-44371.
92. Burchill M.A., Yang J., Vang K.B., Farrar M.A. Interleukin-2 receptor signaling in regulatory T cell development and homeostasis. Immunol Lett Nov 30 2007, 114(1):1-8.
93. Ballesteros-Tato A., Leon B., Graf B.A., Moquin A., Adams P.S., Lund F.E., et al. Interleukin-2 inhibits germinal center formation by limiting T follicular helper differentiation. Immunity May 25 2012, 36(5):847-856.
94. Gürcan H.M., Keskin D.B., Stern J.N.H., Nitzberg M.A., Shekhani H., Ahmed A.R. A review of the current use of rituximab in autoimmune diseases. Int Immunopharmacol Jan 2009, 9(1):10-25.
95. Plaimauer B., Kremer Hovinga J.A., Juno C., Wolfsegger M.J., Skalicky S., Schmidt M., et al. Recombinant ADAMTS13 normalizes von Willebrand factor-cleaving activity in plasma of acquired TTP patients by overriding inhibitory antibodies. J Thromb Haemost May 2011, 9(5):936-944.
96. Haase C., Yu L., Eisenbarth G., Markholst H. Antigen-dependent immunotherapy of non-obese diabetic mice with immature dendritic cells: DC therapy in NOD mice. Clin Exp Immunol Feb 18 2010, 160(3):331-339.
97. + T cells: cellular immune response. Eur J Immunol Jan 2013, 43(1):85-92.
98. 3 or dexamethasone: differential role for PD-L1. Eur J Immunol Nov 2009, 39(11):3147-3159.
99. Van Halteren A.G.S., Tysma O.M., van Etten E., Mathieu C., Roep B.O. 1α,25-Dihydroxyvitamin D3 or analogue treated dendritic cells modulate human autoreactive T cells via the selective induction of apoptosis. J Autoimmun Nov 2004, 23(3):233-239.
100. Karosiene E., Rasmussen M., Blicher T., Lund O., Buus S., Nielsen M. NetMHCIIpan-3.0, a common pan-specific MHC class II prediction method including all three human MHC class II isotypes, HLA-DR, HLA-DP and HLA-DQ. Immunogenetics Oct 2013, 65(10):711-724.